- HIV infection:
- Adults and adolescents (from 12 years of age and weighing ≥ 40 kg): PO 1 tab OD
- Tablet:
- 50mg/300mg/300mg
- Taken with a full glass of water
Dolutegravir: INSTI. It inhibits HIV-1 replication by blocking the strand transfer step of viral DNA integration into the host genome.
Lamivudine: NRTI (cytosine analog). It inhibits HIV reverse transcriptase by viral DNA chain termination.
Tenofovir: NRTI. It inhibits HIV-1 RT by competing with the natural substrate deoxyadenosine 5′-triphosphate and, after incorporation into DNA, by DNA chain termination
- Hypophosphataemia
- Headache
- Insomnia
- Cough
- Nasal symptoms
- Diarrhoea
- Nausea
- Vomiting
- Abdominal pain/cramps
- Flatulence
- Rash
- Hair loss
- Arthralgia
- Muscle disorder
- Hypersensitivity to drug or ingredient
- Dofetilide
- Didanosine
- Aminoglycosides
- Amphotericin B
- Foscarnet
- Ganciclovir
- Pentamidine
- Vancomycin
- Cidofovir
Drug Status
| Availability | Prescription only |
| Pregnancy | Contraindicated |
| Breastfeeding | Contraindicated |
| Schedule | Not scheduled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Dolutegravir Lamivudine and Tenofovir Disoproxil | 50mg/300mg/300mg | Tablet | 30’s | Cipla | Phillips Therapeutics |
| Dolutegravir Lamivudine and Tenofovir Disoproxil | 50mg/300mg/300mg | Tablet | 30’s | Hetero Labs | Unisel Ltd |
| Dolutegravir, Lamivudine and Tenofovir Disoproxil | 50mg/300mg/300mg | Tablet | 30’s | Laurus Labs | Medisel Kenya |
| Dolutegravir, Lamivudine, Tenofovir | 50mg/300mg/300mg | Tablet | 30’s | Aurobindo Pharma | Simba Pharma |